<DOC>
	<DOCNO>NCT00065507</DOCNO>
	<brief_summary>This phase IIIb comparative study entecavir 1.0 mg daily ( QD ) vs. adefovir 10 mg QD patient chronic hepatitis B infection hepatic decompensation . The patient treat 96 week last subject randomize .</brief_summary>
	<brief_title>Comparison Entecavir Adefovir Chronic Hepatitis B Virus ( HBV ) Patients With Hepatic Decompensation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Inclusion ChildPugh ( CP ) score &gt; = 7 Hepatitis B virus ( HBV ) viremia Exclusion Alanine aminotransferase ( ALT ) &gt; 15 x upper limit normal ( ULN ) Human immunodeficiency virus ( HIV ) /hepatitis C virus ( HCV ) /hepatitis D virus ( HDV ) coinfection</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>hepatic decompensation</keyword>
</DOC>